Table 1 |
||||||
|
Differentially spliced genes in colon cancer detected by the exon microarray and confirmed by PCR. |
||||||
|
Gene |
F1 |
R1 |
Known AS Event2 |
Confidence3 |
Preferential Inclusion of Splice Variants4 |
FC5 |
|
|
||||||
|
ACTN1 |
Ex18 |
Ex20 |
19a/19b are MEEs |
Good |
Ex19a in Tumor, 19b in Normal |
-1.05 |
|
ATP2B4 |
Ex20 |
Ex22 |
Ex21 is CE |
Good |
Ex21 in Normal |
+1.53 |
|
VCL |
Ex18 |
Ex20 |
Ex19 is CE |
Good |
Ex19 in Normal |
+1.22 |
|
CALD1 |
Ex5 |
Ex7 |
extended Ex5; Ex6 is CE |
Good |
extended Ex5 + Ex6 in Normal; Ex6 in Normal |
+1.36 |
|
SLC3A2 |
Ex1 |
Ex5 |
Ex2, 3, 4 are CEs |
Good |
Normal skips all exons |
-1.90 |
|
COL6A3 |
Ex2 |
Ex5 |
Ex3 and Ex4 are CEs |
Good |
Ex3 or Ex4 in Tumor |
-1.56 |
|
COL6A3 |
Ex5 |
Ex7 |
Ex6 is CE |
Good |
Ex6 in Tumor |
-1.56 |
|
CTTN |
Ex10 |
Ex14 |
Ex11 is CE |
Good |
Ex11 in Tumor |
-1.21 |
|
FN1 |
Ex24 |
Ex26 |
Ex25 is CE |
Good |
Ex 25 in Normal |
-1.86 |
|
TPM1 |
Ex6 Ex6 |
Ex7 Ex8 |
Ex7/Ex8 are usually MEEs |
Good |
Ex7 in Tumor; Ex8 in Normal |
+1.92 |
|
GK |
Ex19 |
Ex21 |
Ex20 is CE |
Mod. |
Ex20 in Tumor |
-1.01 |
|
MAST2 |
Ex7 Ex5 |
Ex9 Ex9 |
Ex7 alt. start? |
Mod. |
Ex7 Alt. Start in Normal |
+1.26 |
|
LGR5 |
Ex10 Ex11b |
Ex12 Ex12 |
extended Ex11; Ex11b is CE |
Weak |
extended Ex11 + Ex11b in Tumor |
-12.1 |
|
ZAK |
Ex11 |
Ex11b |
Ex11 Alt. 3' end |
Weak |
Alt. 3' end (Ex11b) in Normal |
-1.07 |
|
ZAK |
Ex16 |
Ex18 |
Ex17 appears constitutive |
Weak |
different 3' end of gene |
-1.07 |
|
FXYD6 |
Ex1 |
Ex4 |
Ex2 and Ex3 are rare CEs |
Very Weak |
Ex2 + Ex3 in Tumor |
+2.50 |
|
|
||||||
|
1 Exon locations of the F (forward) and R (reverse) PCR primers. 2 Known Alternative Splicing Event As determined from RefSeq, full length mRNAs and ESTs on the UCSC Genome Browser. 3 Relative confidence in the interpretation. 4 Interpretation of the PCR results in terms of transcript structure. 5 Fold change at the gene level. (-) means that the signal is lower in Tumor. Abbreviations: Ex, exon; CE, cassette exon; MEE, mutually exclusive exon; Alt., alternative. |
||||||
|
Gardina et al. BMC Genomics 2006 7:325 doi:10.1186/1471-2164-7-325 |
||||||